Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Alto Neuroscience, Inc.는 미국에서 임상 단계의 바이오 제약 회사로 활동하고 있습니다. 이 회사의 제품 파이프라인에는 양극성 우울증(BPD) 환자 치료를 위해 2b상 임상 시험 중인 ALTO-100이 포함됩니다. 또한, 주요 우울 장애(MDD) 환자 치료를 위해 2b상 임상 시험 중인, 항우울 특성을 가진 소분자 멜라토닌성 작용제 및 세로토닌성 길항제인 ALTO-300을 개발하고 있습니다. 이 외에도 다음 제품들을 개발 중입니다: 조현병 관련 인지 장애 치료를 위해 2상 개념 증명(POC) 임상 시험 중인